Simulation-based Team Training for Multiprofessional Obstetric Care Teams to Improve Patient Outcome

2017 ◽  
Vol 37 (4) ◽  
pp. 199-200
Author(s):  
A.F. Fransen ◽  
J. van de Ven ◽  
E. Schuit ◽  
A.A.C. van Tetering ◽  
B.W. Mol ◽  
...  
Keyword(s):  
Patient Outcome ◽  
Obstetric Care ◽  
Team Training ◽  
Improve Patient Outcome ◽  
Simulation Based ◽  
Improve Patient

Targeting Bcl-2 Family Proteins in Adult T-Cell Leukemia/Lymphoma: In Vitro and In Vivo Effects of a Novel Bcl-2 Family Inhibitor ABT-737.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 1685-1685
Author(s):  
Kenji Ishitsuka ◽  
Chie Ishikawa ◽  
Fusanori Yotsumoto ◽  
Hiroo Katsuya ◽  
Naoko Kunami ◽  
...  
Keyword(s):  
Patient Outcome ◽  
T Cell ◽  
Conflicts Of Interest ◽  
Interleukin 2 ◽  
Chemotherapeutic Agents ◽  
Improve Patient Outcome ◽  
Type I ◽  
Induced Apoptosis ◽  
Improve Patient

Abstract Abstract 1685 Poster Board I-711 Adult T-cell lymphoma/leukemia (ATLL) is a T-cell malignancy caused by human T-lymphotrophic virus type I (HTLV-I), and its therapeutic outcome is still remains very poor. Therefore, novel therapeutic strategies are needed to improve patient outcome. In this study, we elucidated the therapeutic potential to target anti-apoptotic Bcl-2 family proteins for the treatment of ATLL by using ABT-737 (Abbott Laboratories, Abbott Park, IL, USA), a small molecule inhibitor of Bcl-2, Bcl-XL and Bcl-w. We first validated the rationale of this study by assessing the expression of Bcl-2 family proteins among 25 lymph-node specimens derived from ATLL patients by using immunohistochemistory. Both or either of Bcl-2 and Bcl-XL proteins was highly expressed in 80% of specimens. We next examined the cytotoxicity of ABT-737 against ATLL cell lines. ABT-737 significantly inhibited growth of MT-1, MT-2 and HuT 102 cells with a concentration of 50 percent inhibition (IC50) at 72 h of 2.4, 0.23 and 0.008μM, respectively. We then elucidated the mechanism of growth inhibition induced by ABT-737 using MT-1 and MT-2 cells. ABT-737 induced apoptosis in MT-1, MT-2 cells with cleavage of caspase 9, 3 and PARP. ABT-737 also induced apoptosis in fresh tumor cells derived from patients with ATLL. We next elucidated the potential of ABT-737 to enhance the cytotoxicity induced by conventional chemotherapeutic agents. The interaction between them was evaluated using the Chou-Talalay method by determining the combination index. ABT-737 synergistically enhanced the cytotoxicity and apoptosis induced by either of doxorubicin, vincristine or etoposide, which is a current key drug to treat ATLL. Most importantly, ABT-737 significantly inhibited tumor growth of in vivo ATLL model using SCID mice inoculated by HuT 102 cells subcutaneously. The mean tumor volume, weight and serum level of soluble interleukin-2 receptor á of ABT-737 (100mg/kg/day)-treated mice were significantly lower than those of vehicle-treated mice after treatment for 21 days. Moreover, massive induction of apoptosis in tumors treated by ABT-737 was observed by immunofluorescent TUNEL assay. These results suggest that ABT-737 used either alone or in combination with conventional cytotoxic drugs, represents a promising novel targeted approach to overcome drug resistance and improve patient outcome in ATLL. Disclosures No relevant conflicts of interest to declare.

scholarly journals Hyperplastic Cardiac Sarcoma Recurrence

2015 ◽  
Vol 2015 ◽  
pp. 1-4
Author(s):  
Masood A. Shariff ◽  
Juan A. Abreu ◽  
Farida Durrani ◽  
Eddie Daniele ◽  
Kimberly C. Bowman ◽  
...  
Keyword(s):  
Patient Outcome ◽  
Median Survival ◽  
Multidisciplinary Approach ◽  
Multidisciplinary Care ◽  
Improve Patient Outcome ◽  
Rare Tumors ◽  
Improve Patient

Primary cardiac sarcomas are rare tumors with a median survival of 6–12 months. Data suggest that an aggressive multidisciplinary approach may improve patient outcome. We present the case of a male who underwent resection of cardiac sarcoma three times from the age of 32 to 34. This report discusses the malignant nature of cardiac sarcoma and the importance of postoperative multidisciplinary care.

scholarly journals The Effect of Simulation-Based Neonatal Emergency Team Training on Clinical Performance and Patient Outcome: A Systematic Review

2020 ◽  
Author(s):  
Morten S. Lindhard ◽  
Signe Thim ◽  
Henrik Sehested Laursen ◽  
Anders Wester Schram ◽  
Charlotte Paltved ◽  
...  
Keyword(s):  
Patient Outcome ◽  
Systematic Review ◽  
Neonatal Mortality ◽  
Team Performance ◽  
Simulation Training ◽  
Clinical Performance ◽  
Team Training ◽  
Developed Countries ◽  
Risk Of Bias ◽  
Simulation Based

Abstract BackgroundA number of neonatal simulation-training programmes have been deployed during the last decade, and a growing number of studies have investigated effects of simulation-based team training. However, the body of evidence remains to be compiled. Therefore, we performed a systematic review on the effects of simulation-based team training on clinical performance and patient outcome.MethodsThe review was conducted according to the preferred reporting items for systematic review and meta-analysis (PRISMA). We included studies on team training in emergency neonatal settings with reported outcome on clinical performance and patient outcome. Two reviewers independently selected articles and assessed risk-of-bias using the Cochrane risk-of-bias tool 2.0 and the Newcastle-Ottawa quality assessment scale. Kirkpatricks’ model for evaluation of training programs provided the framework for a narrative synthesis.ResultsWe screened 1,434 titles and abstracts, evaluated 173 full-texts for eligibility, and included 24 studies. We identified only two studies with neonatal mortality outcome, and they had significant methodological limitations, and no conclusion could be reached regarding effects of simulation training in developed countries. Considering clinical performance, randomized studies showed improved team performance in simulated re-evaluations 3 and 6 months after the intervention.ConclusionsSimulation-based team training in neonatal resuscitation improves team performance and technical performance in simulation-based evaluations 3 to 6 months later. The current evidence was insufficient to conclude on neonatal mortality after simulation-based team training, since no studies were available from developed countries. Future research should include patient outcomes or clinical proxies of treatment quality whenever possible.

Sign in / Sign up

Export Citation Format

Share Document